NYSEARCA:OLEM

iPath Pure Beta Crude Oil ETN Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
$12.58
$12.63
52-Week Range N/A
Volume200 shs
Average Volume15,203 shs
Market Capitalization$31.22 million
P/E RatioN/A
Dividend Yield0.00%
BetaN/A

Receive OLEM News and Ratings via Email

Sign-up to receive the latest news and ratings for iPath Pure Beta Crude Oil ETN and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Barclays Capital
Fund NameiPath Pure Beta Crude Oil ETN
Tax ClassificationExchange-Traded Note
SymbolNYSEARCA:OLEM
Inception Date4/20/2011
Fund Manager
WebN/A
PhoneN/A

Fund Focus

Asset ClassCommodities
BenchmarkBarclays Capital WTI Crude Oil Pure Beta TR Index
CategoryEnergy
FocusCrude Oil
Development LevelBlended Development
RegionGlobal

Fund Statistics

Assets Under Management$31.32 million
Average Daily Volume$126.00
Discount/Premium-0.04%

ETF Expenses

Management Fee0.00%
Other Expenses0.00%
Total Expenses0.00%
Fee Waiver0.00%
Net Expenses0.75%

Administrator, Advisor and Custodian

Administrator
Advisor
Custodian
Distributor
Transfer Agent
Trustee
Lead Market MakerSusquehanna

speech bubbles
speech bubbles











iPath Pure Beta Crude Oil ETN (NYSEARCA:OLEM) Frequently Asked Questions

What stocks does MarketBeat like better than iPath Pure Beta Crude Oil ETN?

Wall Street analysts have given iPath Pure Beta Crude Oil ETN a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iPath Pure Beta Crude Oil ETN wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are some of iPath Pure Beta Crude Oil ETN's key competitors?

What other stocks do shareholders of iPath Pure Beta Crude Oil ETN own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iPath Pure Beta Crude Oil ETN investors own include Amarin (AMRN), Aduro Biotech (ADRO), (ALT), Armata Pharmaceuticals (ARMP), CRISPR Therapeutics (CRSP), Micron Technology (MU), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV) and Vaxart (VXRT).

What is iPath Pure Beta Crude Oil ETN's stock symbol?

iPath Pure Beta Crude Oil ETN trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "OLEM."

How do I buy shares of iPath Pure Beta Crude Oil ETN?

Shares of OLEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does iPath Pure Beta Crude Oil ETN make?

iPath Pure Beta Crude Oil ETN has a market capitalization of $0.00.


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.